Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Upstream Bio, Inc.NASDAQ: UPB
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$374.81M, compared with -$218.05M a year earlier.
Context
- Retained earnings amounted to 117.8% of total assets at the end of Q1 FY2026, up 70.0 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -71.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (334.22M) USD
- Year-over-year change
- -75.2%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (334.22M) | -75.2% |
| FY2024 | 2024-12-31 | (190.78M) | -49.1% |
| FY2023 | 2023-12-31 | (127.97M) | -19.1% |
| FY2022 | 2022-12-31 | (107.44M) | — |
Retained Earnings vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so retained earnings is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -71.9% is the 9th highest of 10, against a peer median of -18.6%.
- Retained earnings amounts to 117.8% of total assets for UPB, versus a peer median of 231.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
UPBUpstream Bio, Inc. | Mar 2026 | -$374.81M USD | -71.9% | — | 117.8% |
| Sep 2026 | -€716.58M EUR | -34.6% | — | 242.9% | |
| Mar 2026 | -$846.12M USD | -101.0% | — | 113.2% | |
| Sep 2026 | -$881.62M USD | -22.7% | — | 112.1% | |
| Sep 2026 | -$1.33B USD | -24.8% | — | 120.8% | |
| Mar 2026 | -$1.35B USD | -15.7% | — | 231.7% | |
| Mar 2026 | -$1.55B USD | -18.6% | — | 327.8% | |
| Jun 2026 | -$2.17B USD | -15.2% | — | 224.5% | |
| Mar 2026 | -$2.69B USD | -17.2% | — | 354.0% | |
| Mar 2026 | -$4.58B USD | -2.0% | — | 438.8% | |
| Peer median (excluding UPB) | — | -18.6% | — | 231.7% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.